GSA Capital Partners LLP Purchases Shares of 632,131 Gain Therapeutics, Inc. $GANX

Key Points

• GSA Capital Partners acquired 632,131 Gain Therapeutics shares worth approximately $1.28 million, taking a 1.48% stake. Institutional investors and hedge funds collectively own 11.97% of the company.
• Analyst sentiment remains generally positive: five analysts rate GANX a Buy and one rates it a Sell, producing a consensus “Moderate Buy” rating and a $7.50 price target.
• Gain Therapeutics shares opened at $2.04 after a 3.8% decline, while the company reported a quarterly loss of $0.11 per share—better than the expected $0.14 loss.

GSA Capital Partners LLP acquired a new position in Gain Therapeutics, Inc. (NASDAQ:GANX - Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 632,131 shares of the company's stock, valued at approximately $1,283,000. GSA Capital Partners LLP owned 1.48% of Gain Therapeutics at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Marshall Wace LLP increased its position in shares of Gain Therapeutics by 849.3% during the fourth quarter. Marshall Wace LLP now owns 1,662,293 shares of the company's stock valued at $5,353,000 after purchasing an additional 1,487,186 shares during the period. Potomac Capital Management Inc. bought a new position in Gain Therapeutics in the fourth quarter worth $3,252,000. Jane Street Group LLC boosted its stake in Gain Therapeutics by 234.5% during the fourth quarter. Jane Street Group LLC now owns 242,328 shares of the company's stock worth $780,000 after buying an additional 169,878 shares in the last quarter. LPL Financial LLC acquired a new stake in Gain Therapeutics during the fourth quarter worth $343,000. Finally, State Street Corp increased its holdings in Gain Therapeutics by 72.9% in the 4th quarter. State Street Corp now owns 157,537 shares of the company's stock valued at $507,000 after buying an additional 66,400 shares during the period. Institutional investors and hedge funds own 11.97% of the company's stock.

Analysts Set New Price Targets

GANX has been the subject of a number of recent research reports. Roth Capital restated a "buy" rating on shares of Gain Therapeutics in a research note on Tuesday, May 12th. BTIG Research reiterated a "buy" rating and set a $5.00 target price on shares of Gain Therapeutics in a research report on Tuesday, August 11th. Weiss Ratings cut shares of Gain Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday, June 9th. Wall Street Zen raised shares of Gain Therapeutics from a "strong sell" rating to a "sell" rating in a research report on Sunday, June 21st. Finally, HC Wainwright reissued a "buy" rating and issued a $8.00 price target on shares of Gain Therapeutics in a research report on Wednesday, July 1st. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Gain Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $7.50.

Gain Therapeutics Stock Down 3.8%

GANX opened at $2.04 on Tuesday. The firm's 50-day simple moving average is $1.81 and its 200-day simple moving average is $1.93. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.36 and a current ratio of 4.36. Gain Therapeutics, Inc. has a twelve month low of $1.53 and a twelve month high of $4.34. The firm has a market cap of $89.03 million, a price-to-earnings ratio of -4.08 and a beta of 0.19.

Gain Therapeutics (NASDAQ:GANX - Get Free Report) last announced its earnings results on Tuesday, August 11th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.14) by $0.03. Equities research analysts anticipate that Gain Therapeutics, Inc. will post -0.52 EPS for the current fiscal year.

Gain Therapeutics Profile

Gain Therapeutics, Inc NASDAQ: GANX is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain's lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source